2023
Complex Percutaneous Coronary Intervention Outcomes in Older Adults
Hanna J, Wang S, Kochar A, Park D, Damluji A, Henry G, Ahmad Y, Curtis J, Nanna M. Complex Percutaneous Coronary Intervention Outcomes in Older Adults. Journal Of The American Heart Association 2023, 12: e029057. PMID: 37776222, PMCID: PMC10727245, DOI: 10.1161/jaha.122.029057.Peer-Reviewed Original ResearchConceptsNoncomplex percutaneous coronary interventionsComplex percutaneous coronary interventionStable ischemic heart diseasePercutaneous coronary interventionIschemic heart diseaseTarget lesion revascularizationEvent-free survivalHeart diseaseOlder adultsCause deathLesion revascularizationClinical characteristicsElective percutaneous coronary interventionPercutaneous coronary intervention outcomesWorse event-free survivalMedical therapy useCox regression modelLarge health systemNoncardiac comorbiditiesRevascularization riskCoronary interventionTherapy useClinical outcomesDisease featuresLower riskFactor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis
Park D, An S, Kumar A, Malhotra S, Jolly N, Kaur A, Kattoor A, Doukky R, Kalra A, Vij A. Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis. American Journal Of Cardiovascular Drugs 2022, 22: 633-645. PMID: 35781867, DOI: 10.1007/s40256-022-00541-w.Peer-Reviewed Original ResearchConceptsNet adverse clinical eventsDuration of DAPTPercutaneous coronary interventionNetwork meta-analysisShorter duration of DAPTStent thrombosisMyocardial infarctionDrug-eluting stentsMeta-analysisResultsSeventeen randomized controlled trialsSystematic reviewAdverse cardiac eventsAdverse clinical eventsFrequentist network meta-analysesRisk of myocardial infarctionBackgroundDual antiplatelet therapyMonths of DAPTRandomized controlled trialsRandom-effects modelNetwork meta-analysesClinical presentationNo significant differenceAntiplatelet therapyMethodsThe present studyCardiac events